[1] Rumgay H, Ferlay J, de Martel C, et al. Global, regional and national burden of primary liver cancer by subtype[J]. Eur J Cancer, 2022, 161:108-118. [2] Chen W, Chiang C L, Dawson L A. Efficacy and safety of radiotherapy for primary liver cancer[J]. Chin Clin Oncol, 2021, 10(1):9. [3] Shao Z, Liu X, Peng C, et al. Combination of transcatheter arterial chemoembolization and portal vein embolization for patients with hepatocellular carcinoma: a review[J]. World J Surg Oncol, 2021, 19(1):293. [4] Liu X, Li H, Wang F, et al. Transhepatectomy combined with arterial chemoembolization and transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a clinical prognostic analysis[J]. BMC Gastroenterol, 2023, 23(1):299. [5] Wu J, Wu J, Li S, et al. Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a treatment with Chinese characteristics[J]. Biosci Trends, 2024, 18(1):42-48. [6] Bai H, Gao P, Gao H, et al. Improvement of survival rate for patients with hepatocellular carcinoma using transarterial chemoembolization in combination with three-dimensional conformal radiation therapy: a meta-analysis[J]. Med Sci Monit, 2016, 22:1773-1781. [7] 林根来, 曾昭冲, 吴铮, 等. 常规分割三维适形放疗对不可切除的原发性肝细胞癌的疗效分析[J]. 中华放射医学与防护杂志, 2012, 32(3):311-313. [8] 唐亮, 陈曦, 王文高, 等. TACE联合直线加速器三维适形放疗治疗中晚期原发性肝癌患者近期临床疗效研究[J]. 实用肝脏病杂志, 2023, 26(3):416-419. [9] 中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版)[J]. 中华肝脏病杂志, 2024, 32(7):581-630. [10] 张百红, 岳红云. 实体瘤疗效评价标准简介[J]. 国际肿瘤学杂志, 2016, 43(11):845-847. [11] Féray C, Campion L, Mathurin P, et al. TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: a randomised controlled trial[J]. JHEP Rep, 2023, 5(4):100689. [12] Wu Q Q, Chen Y X, Zheng T T, et al. Which is the best combination of surgery for hepatocellular carcinoma with hepatic/portal vein thrombosis in China: a network meta-analysis of randomized controlled trials[J]. J BUON, 2021, 26(3):889-896. [13] Gao Y, Xu Y, Wang Y, et al. Clinical features and prognostic factors of patients with inoperable hepatocellular carcinoma treated with chemotherapy: a population-based study[J]. J Gastrointest Oncol, 2024, 15(3):1122-1140. [14] 高金龙, 王海峰, 李娜, 等. 自MR-T2图像勾画肝细胞癌患者放疗靶区精度研究[J]. 实用肝脏病杂志, 2021, 24(4):565-568. [15] Scorsetti M, Comito T, Cozzi L, et al. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT)[J]. J Cancer Res Clin Oncol, 2015, 141(7):1301-1309. [16] 王超, 马士亮, 曹邱婷, 等. 低剂量全肝灌注CT评价肝细胞癌TACE术后残余肿瘤活性[J]. 影像诊断与介入放射学, 2022, 31(6):446-451. |